Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX plus apatinib as second-line therapy in metastatic colorectal cancer
ChiCTR-OIC-17011734Phase 2Not yet recruiting
- Sponsor
- Tongji Medical College
- Start
- Aug 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and FOLFOX in colorectal cancer (CRC), sponsored by Tongji Medical College. Primary endpoint: Progression-free survival. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
RivoceranibFOLFOX
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-OIC-17011734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011734.